CLCA2 suppresses the proliferation, migration and invasion of cervical cancer

Zhang,Peijin; Lin,Yang; Liu,Yaqiong

doi:10.3892/etm.2021.10208

CLCA2 suppresses the proliferation, migration and invasion of cervical cancer

Authors:
- Peijin Zhang
- Yang Lin
- Yaqiong Liu
View Affiliations

Affiliations: Department of Gynecology, Tianjin Central Hospital of Gynecology Obstetrics, Tianjin 300100, P.R. China, Department of Gynecology and Obstetrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong 510000, P.R. China
Published online on: May 18, 2021 https://doi.org/10.3892/etm.2021.10208
Article Number: 776

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ca²⁺‑activated Cl^‑ channel A2 (CLCA2), a tumor suppressor, is associated with the development of several cancers. However, little is known about CLCA2 in human cervical cancer. Therefore, the aim of the present study was to investigate the effects of CLCA2 on cervical cancer. Reverse transcription‑quantitative (RT‑q)PCR was used to examine the mRNA expression levels of CLCA2 in eight pairs of cervical cancer tissues. Immunohistochemistry was used to investigate CLCA2 protein expression in 144 archived cervical cancer specimens. The association of the CLCA2 with clinicopathological parameters was statistically evaluated. Cell proliferation and invasion capability were examined by MTT and Transwell assays, respectively. RT‑qPCR analysis revealed that CLCA2 expression was decreased in cervical cancer compared with that in adjacent normal tissues. The expression levels of CLCA2 in patients were correlated with tumor stage (P=0.028), tumor size (P=0.009), and human papillomavirus (HPV) infection status (P=0.041). In addition, CLCA2 upregulation was associated with longer overall and recurrence‑free survival time after surgery (P=0.016 and P=0.009, respectively). Multivariate Cox regression analysis demonstrated that CLCA2 expression had a predictive value for overall survival of patients with cervical cancer (P=0.017 and P=0.025, respectively). Knockdown of CLCA2 by small interfering RNA suppressed tumor cell proliferation and migration. Mechanistically, CLCA2 was involved in Wnt/β‑catenin signaling. In conclusion, the results of the present study demonstrated that CLCA2 suppressed the proliferation, migration and invasion of cervical cancer cells, and that CLCA2 may be a potential therapeutic target of cervical cancer.

View Figures

View References

1	Peiretti M, Zapardiel I, Zanagnolo V, Landoni F, Morrow CP and Maggioni A: Management of recurrent cervical cancer: A review of the literature. Surg Oncol. 21:e59–e66. 2012.PubMed/NCBI View Article : Google Scholar
2	Cerrotta A, Gardan G, Cavina R, Raspagliesi F, Stefanon B, Garassino I, Musumeci R, Tana S and De Palo G: Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose. Eur J Gynaecol Oncol. 23:115–119. 2002.PubMed/NCBI
3	Elble RC, Walia V, Cheng HC, Connon CJ, Mundhenk L, Gruber AD and Pauli BU: The putative chloride channel hCLCA2 has a single C-terminal transmembrane segment. J Biol Chem. 281:29448–29454. 2006.PubMed/NCBI View Article : Google Scholar
4	Walia V, Ding M, Kumar S, Nie D, Premkumar LS and Elble RC: hCLCA2 is a p53-inducible inhibitor of breast cancer cell proliferation. Cancer Res. 69:6624–6632. 2009.PubMed/NCBI View Article : Google Scholar
5	Connon CJ, Kawasaki S, Yamasaki K, Quantock AJ and Kinoshita S: The quantification of hCLCA2 and colocalisation with integrin beta4 in stratified human epithelia. Acta Histochem. 106:421–425. 2005.PubMed/NCBI View Article : Google Scholar
6	Ramena G, Yin Y, Yu Y, Walia V and Elble RC: CLCA2 interactor EVA1 is required for mammary epithelial cell differentiation. PLoS One. 11(e0147489)2016.PubMed/NCBI View Article : Google Scholar
7	Bart G, Hämäläinen L, Rauhala L, Salonen P, Kokkonen M, Dunlop TW, Pehkonen P, Kumlin T, Tammi MI, Pasonen-Seppänen S and Tammi RH: rClca2 is associated with epidermal differentiation and is strongly downregulated by ultraviolet radiation. Br J Dermatol. 171:376–387. 2014.PubMed/NCBI View Article : Google Scholar
8	Grigsby PW, Massad LS, Mutch DG, Powell MA, Thaker PH, McCourt C, Hagemann A, Fuh K, Kuroki L, Schwarz JK, et al: FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival. Gynecol Oncol. 157:639–643. 2020.PubMed/NCBI View Article : Google Scholar
9	Wang J, Ou J, Guo Y, Dai T, Li X, Liu J, Xia M, Liu L and He M: TBLR1 is a novel prognostic marker and promotes epithelial-mesenchymal transition in cervical cancer. Br J Cancer. 111:112–124. 2014.PubMed/NCBI View Article : Google Scholar
10	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
11	Wang B, Zhang L and Zhao L, Zhou R, Ding Y, Li G and Zhao L: LASP2 suppresses colorectal cancer progression through JNK/p38 MAPK pathway meditated epithelial-mesenchymal transition. Cell Commun Signal. 15(21)2017.PubMed/NCBI View Article : Google Scholar
12	Park S, Kim J, Eom K, Oh S, Kim S, Kim G, Ahn S, Park KH, Chung D and Lee H: microRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer. BMC Cancer. 19(419)2019.PubMed/NCBI View Article : Google Scholar
13	Pauli BU, Abdel-Ghany M, Cheng HC, Gruber AD, Archibald HA and Elble RC: Molecular characteristics and functional diversity of CLCA family members. Clin Exp Pharmacol Physiol. 27:901–905. 2000.PubMed/NCBI View Article : Google Scholar
14	Pawlowski K, Lepisto M, Meinander N, Sivars U, Varga M and Wieslander E: Novel conserved hydrolase domain in the CLCA family of alleged calcium-activated chloride channels. Proteins. 63:424–439. 2006.PubMed/NCBI View Article : Google Scholar
15	Fuller CM, Ji HL, Tousson A, Elble RC, Pauli BU and Benos DJ: Ca(2+)-activated Cl(-) channels: A newly emerging anion transport family. Pflugers Archiv. 443 (Suppl 1):S107–S110. 2001.PubMed/NCBI View Article : Google Scholar
16	Li X, Cowell JK and Sossey-Alaoui K: CLCA2 tumour suppressor gene in 1p31 is epigenetically regulated in breast cancer. Oncogene. 23:1474–1480. 2004.PubMed/NCBI View Article : Google Scholar
17	Zhao G, Chen J, Deng Y, Gao F, Zhu J, Feng Z, Lv X and Zhao Z: Identification of NDRG1-regulated genes associated with invasive potential in cervical and ovarian cancer cells. Biochem Biophys Res Commun. 408:154–159. 2011.PubMed/NCBI View Article : Google Scholar
18	Sasaki Y, Koyama R, Maruyama R, Hirano T, Tamura M, Sugisaka J, Suzuki H, Idogawa M, Shinomura Y and Tokino T: CLCA2, a target of the p53 family, negatively regulates cancer cell migration and invasion. Cancer Biol Ther. 13:1512–1521. 2012.PubMed/NCBI View Article : Google Scholar
19	Qiang YY, Li CZ, Sun R, Zheng LS, Peng LX, Yang JP, Meng DF, Lang YH, Mei Y, Xie P, et al: Along with its favorable prognostic role, CLCA2 inhibits growth and metastasis of nasopharyngeal carcinoma cells via inhibition of FAK/ERK signaling. J Exp Clin Cancer Res. 37(34)2018.PubMed/NCBI View Article : Google Scholar
20	Jiang MM, Gao L, Jing Y, Ding Y, Xu YY, Zhou MH, Ma C, Wang N, Wang W, Han XP, et al: Rapid detection of AML1 associated fusion genes in patients with adult acute myeloid leukemia and its clinical significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 21:821–829. 2013.PubMed/NCBI View Article : Google Scholar
21	Man Y, Cao J, Jin S, Xu G, Pan B, Shang L, Che D, Yu Q and Yu Y: Newly identified biomarkers for detecting circulating tumor cells in lung adenocarcinoma. Tohoku J Exp Med. 234:29–40. 2014.PubMed/NCBI View Article : Google Scholar